Susan Mani, MD, vice president of Clinical Transformation and Ambulatory Quality at LifeBridge Health, discusses barriers to understanding the return on investment of social determinants of health initiatives.
Susan Mani, MD, vice president of Clinical Transformation and Ambulatory Quality at LifeBridge Health, discusses barriers to understanding the return on investment of social determinants of health initiatives.
Transcript
What are some barriers to understanding the return on investment of social determinants of health initiatives?
I think the biggest barrier that we had initially was really trying to figure out how to put dollar amounts to work that we did. Often times in health systems, we’re used to thinking of traditional service lines—cardiology, orthopedics, procedural based, visit based. So, very frequently, it’s easy to use that language. How do you think of it from a population health standpoint or from a care management standpoint? So, we really had to tweak the definition a little bit differently when it came to care coordination events, and once we created that language it became a lot easier to show a return on investment. How well were we actually touching our potential patients? Were our patients tiered?
We were thinking about high risk versus rising risk or low risk, because every patient is not going to need the same intensity of care. And the other thing we started to look at was the intensity of touch. For some of our patients, like our high-risk patients, they’re going to need a lot more intensity of touch, as I call them. For example, in a clinician’s office, you’re thinking about follow-up visits. Well, for our care coordination teams, it might mean those phone calls, it might mean how frequently are they keeping up with the care plan. All of those are actually touch points that you want to quantify. And then what are the referrals to services? Over time, if we have to start thinking about what community resources did we link our patients to, how are we getting them back into primary care successfully so they’re following up with their physicians. All of those are very important when you’re calculating your return on investment because that is the true RVU [relative value unit] in a population health standpoint.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More